As we age, our cells age and so do our healing processes. The scientists at RESTEM have dedicated years to the research and development of novel cell-based therapies with the goal of effectively restoring immune health, among other healing properties.
Our research scientists have identified a novel umbilical cord subset of cells that we describe as Umbilical Cord Lining Stem Cells (ULSCs), ethically obtained post-partum, that have properties of adult Mesenchymal Stem Cells (MSCs), but at a much more youthful state. In preclinical and clinical studies, we have shown that these ULSCs also have a superior immunomodulatory profile versus other types of MSCs such as bone marrow or fat MSCs.
To bring this transformative research to human clinical trials, a multi-year development effort was initiated to isolate these unique ULSCs. For over a decade, we have developed commercial-scale production methods that include cryopreservation processes to maintain their viability and youthful phenotype, as well as therapeutic activity, to get to a clinical-grade therapy.
Microscopic image of our cells
RESTEM’s proprietary cells are reproduced and preserved under current Good Manufacturing Processes.
Through our proprietary novel stem cell isolation methods, we determined that ULSCs were the most potent stem cells. We spent years perfecting our delicate approach to culturing our cells and maintaining their youthful and viable state. State-of-the-art laboratory expertise in telomere biology and immunology assures that we are not only producing ULSCs at commercial quantities, millions of doses, but also superior cells with optimized therapeutic potential.
Our cells are produced according to FDA standards for all infectious disease testing and have been screened for chromosomal aberrations by growing the cells up through senescence. All donors are negative for common viral infections, such as CMV and EBV, which affect approximately 75% of the world population. We aim to deliver the safest cell therapeutics in the world.